CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.47%81.210.9%$648.72m
CELGCelgene Corporation
-10.76%121.331.1%$640.82m
AMGNAmgen Inc.
-0.63%182.961.1%$453.41m
BIIBBiogen Inc.
-1.26%338.101.2%$410.25m
REGNRegeneron Pharmaceuticals, Inc.
-1.81%432.982.7%$314.62m
VRTXVertex Pharmaceuticals Incorporated
0.02%154.631.9%$217.79m
INCYIncyte Corporation
-0.07%114.192.5%$202.03m
ALXNAlexion Pharmaceuticals, Inc.
-1.08%138.941.9%$183.38m
ALNYAlnylam Pharmaceuticals, Inc
-0.82%114.6810.7%$157.13m
EXELExelixis, Inc.
-1.06%27.176.5%$135.00m
ILMNIllumina, Inc.
2.29%209.883.5%$132.21m
BLUEBluebird Bio, Inc.
2.22%142.5517.3%$118.24m
BMRNBioMarin Pharmaceutical Inc.
-0.43%87.754.4%$113.37m
SRPTSarepta Therapeutics, Inc.
2.41%51.9416.9%$108.74m
CLVSClovis Oncology, Inc.
0.95%77.5016.5%$103.06m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus or human papillomavirus co-infected patients. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.